Europeiska unionen - svenska - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

hisamitsu italia s.r.l. - d-kamfer; hydroxietylsalicylat; levomentol; metylsalicylat - kutan spray, lösning - metylsalicylat 17,5 mg aktiv substans; hydroxietylsalicylat 17,5 mg aktiv substans; d-kamfer 30 mg aktiv substans; levomentol 32 mg aktiv substans - salicylsyraderivat

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

hisamitsu italia s.r.l. - kamfer, racemisk; levomentol; metylsalicylat - medicinskt plåster - butylhydroxitoluen hjälpämne; levomentol 32,7 mg aktiv substans; metylsalicylat 36,1 mg aktiv substans; kamfer, racemisk 7,1 mg aktiv substans - salicylsyraderivat

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

wick pharma, zweigniederlassung der procter & gamble gmbh - eukalyptusolja; kamfer, racemisk; levomentol; terpentinolja; tymol - salva - tymol 2,5 mg aktiv substans; kamfer, racemisk 50 mg aktiv substans; levomentol 27,5 mg aktiv substans; terpentinolja 50 mg aktiv substans; eukalyptusolja 15 mg aktiv substans - Övriga medel mot förkylning

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

evolan pharma ab - kajeputolja; kamfer, racemisk; kryddnejlikolja; levomentol - salva - kryddnejlikolja 15 mg aktiv substans; kajeputolja 130 mg aktiv substans; kamfer, racemisk 100 mg aktiv substans; levomentol 120 mg aktiv substans - utvärtes medel vid led- och muskelsmärtor

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

evolan pharma ab - kajeputolja; kamfer, racemisk; kryddnejlikolja; levomentol; myntaolja, delvis avmentoliserad - salva - levomentol 100 mg aktiv substans; kajeputolja 70 mg aktiv substans; kamfer, racemisk 110 mg aktiv substans; kryddnejlikolja 50 mg aktiv substans; myntaolja, delvis avmentoliserad 60 mg aktiv substans - utvärtes medel vid led- och muskelsmärtor

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

evolan pharma ab - kajeputolja; kamfer, racemisk; kryddnejlikolja; levomentol; myntaolja, delvis avmentoliserad - salva - levomentol 80 mg aktiv substans; myntaolja, delvis avmentoliserad 160 mg aktiv substans; kryddnejlikolja 15 mg aktiv substans; kajeputolja 130 mg aktiv substans; kamfer, racemisk 110 mg aktiv substans - utvärtes medel vid led- och muskelsmärtor

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

b. braun medizintechnologie gmbh - natriumklorid; natriumvätekarbonat - hemofiltrationsvätska - natriumvätekarbonat 3,59 mg aktiv substans; natriumklorid 6,18 mg aktiv substans - hemofiltrationsvätskor

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

campus pharma ab - epoprostenolnatrium - pulver och vätska till infusionsvätska, lösning - 0,5 mg - epoprostenolnatrium 0,531 mg aktiv substans; mannitol hjälpämne - epoprostenol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

campus pharma ab - epoprostenolnatrium - pulver och vätska till infusionsvätska, lösning - 1,5 mg - mannitol hjälpämne; epoprostenolnatrium 1,593 mg aktiv substans - epoprostenol